Safety and Blood Level Study of Unit Dose Budesonide
Status:
Completed
Trial end date:
2006-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the tolerability and pharmacokinetics of three doses
of MAP0010 (Unit Dose Budesonide) compared with Pulmicort Respules® (Budesonide) in healthy
volunteers.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Collaborators:
MAP Pharmaceuticals, Inc., a wholly owned subsidiary of Allergan Q-Pharm Pty Limited